A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Fibroblast growth factor 1 (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors CardioVascular BioTherapeutics Inc
- 25 Jan 2018 Planned End Date changed from 31 Dec 2014 to 1 Jun 2020.
- 25 Jan 2018 Planned initiation date changed from 1 Dec 2014 to 1 Jun 2019.
- 15 Apr 2014 New trial record